DSC3 and metastatic malignant neoplasm: SERPINB5 has been indicated to inhibit tumor progression [56], DSC3 downregulation has been linked with several cancer types [57] and GABRP over-expression has been linked with poor prognosis, metastatic cancer, basal-like breast cancer [58–60].